Evidence map›Paper›PMID 40147770›Full record

ArticleThe Journal of biological chemistry2025

The N-terminal ELR

Sean Patrick Giblin, Sophie McKenna, Stephen Matthews, Shiranee Sriskandan, James Edward Pease

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. SpyCEP dismantles neutrophil immunity via disorder-driven chemokine remodeling and GAG targeting.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sean Patrick GiblinNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Sophie McKennaDepartment of Life Sciences, Imperial College London, London, United Kingdom.
Stephen MatthewsDepartment of Life Sciences, Imperial College London, London, United Kingdom; Centre for Bacterial Resistance Biology, Imperial College London, London, United Kingdom.
Shiranee SriskandanCentre for Bacterial Resistance Biology, Imperial College London, London, United Kingdom; Department of Infectious Disease, Imperial College London, London, United Kingdom.
James Edward PeaseNational Heart and Lung Institute, Imperial College London, London, United Kingdom. Electronic address: j.pease@imperial.ac.uk.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Streptococcus pyogenes (Group A Streptococcus or GAS) is a major human pathogen for which an effective vaccine is highly desirable. Invasive S. pyogenes strains evade the host immune response in part by producing a cell envelope protease, SpyCEP. This neutralizes chemokines containing an N-terminal Glu-Leu-Arg motif (ELR

Indexed as

Bacterial ProteinsInterleukin-8ProteolysisStreptococcus pyogenesAmino Acid MotifsHumansPeptide HydrolasesBacterial ProteinsCXCL8 protein, humanInterleukin-8Peptide HydrolasesSpyCEP protein, Streptococcus pyogeneschemokineCXCL8enzyme degradationproteaserecombinant protein expressionSpyCEPStreptococcus pyogenes (S. pyogenes)

Identifiers

PMID40147770
PMCPMC12022482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.